Research LSD FDA-Approved Clinical Trials for Anxiety

[Electrum1]

MindMed got FDA breakthrough designation for their LSD trial last month

Food and Drug Administration has granted breakthrough designation for its MM120 LSD-based treatment for generalized anxiety disorder

“That MM120 exhibited rapid and robust efficacy, solidly sustained for 12 weeks after a single dose, is truly remarkable,” said David Feifel, professor emeritus of psychiatry at the University of California, San Diego, and director of the Kadima Neuropsychiatry Institute in La Jolla, Calif. Feifel was an investigator on the MM120 study.

MindMed is now planning to hold end-of-Phase 2 meetings with the FDA in the first half of the year and aims to initiate a Phase 3 trial in the second half of 2024.

https://www.marketwatch.com/story/mindmeds-stock-jumps-24-after-fda-grants-breakthrough-designation-to-lsd-therapy-for-a-form-of-anxiety-c5d230c5

Positive phase 2 results press release:

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

-A single oral administration of MM120 100 µg met its key secondary endpoint and maintained a clinically and statistically significant…...

ir.mindmed.co

 

[Baphomet64]

\m/ badass